Candel Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Candel Therapeutics, Inc. (CADL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-55.18-37.94-18.79-36.12-17.68
Depreciation & Amortization0.990.960.780.230.09
Stock Based Compensation5.313.092.312.962.11
Change in Working Capital0.35-0.530.07-0.881.77
Change in Accounts Payable-0.190.05-1.210.670.29
Change in Other Working Capital0.66-0.380.59-1.421.61
Other Operating Activities0.66-0.620.5911.034.64
Net Cash from Operating Activities-27.02-34.24-31.42-22.22-9.07
Investing Activities
Capital Expenditures-0.02-0.46-1.30-1.84-1.48
Purchases of Investments0.000.000.000.0039.93
Net Cash from Investing Activities-0.02-0.28-1.30-1.8438.46
Financing Activities
Debt Repayment-9.170.000.000.000.00
Common Stock Issued101.760.000.0671.800.03
Common Stock Repurchased0.00-0.120.000.000.00
Other Financing Activities1.69-0.120.000.000.00
Net Cash from Financing Activities94.28-0.1219.9771.800.49
Summary
Net Change in Cash67.24-34.65-12.7447.7529.87
Cash at Beginning of Period35.6870.3283.0735.320.00
Cash at End of Period102.92-36.5170.3283.070.00
Free Cash Flow-27.04-34.70-32.72-24.05-10.55
Supplemental Disclosures
Interest Paid1.802.151.150.000.00
Income Taxes Paid0.000.000.180.030.09